• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (NY: ANRO )

    11.62 +0.52 (+4.68%)
    Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 55,665
    Open 11.03
    Bid (Size) 11.10 (1)
    Ask (Size) 11.78 (1)
    Prev. Close 11.10
    Today's Range 10.94 - 11.69
    52wk Range 9.400 - 24.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
    From Alto Neuroscience, Inc.
    Via Business Wire
    Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
    From Alto Neuroscience, Inc.
    Via Business Wire

    Performance

    YTD
    -43.86%
    -43.86%
    1 Month
    +5.64%
    +5.64%
    3 Month
    -18.05%
    -18.05%
    6 Month
    -43.86%
    -43.86%
    1 Year
    -43.86%
    -43.86%

    More News

    Read More
    Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On
    Via InvestorPlace
    Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
    From Alto Neuroscience, Inc.
    Via Business Wire
    Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
    From Alto Neuroscience, Inc.
    Via Business Wire
    ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024
    Via InvestorPlace
    Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Alto Neuroscience, Inc.
    Via Business Wire
    Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
    From Alto Neuroscience, Inc.
    Via Business Wire
    Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
    Via Benzinga
    Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
    From Alto Neuroscience, Inc.
    Via Business Wire
    Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
    From Alto Neuroscience, Inc.
    Via Business Wire
    Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
    From Alto Neuroscience, Inc.
    Via Business Wire
    Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
    From Alto Neuroscience, Inc.
    Via Business Wire
    Alto Neuroscience to Participate in Upcoming Investor Conferences
    From Alto Neuroscience, Inc.
    Via Business Wire
    Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
    From Alto Neuroscience, Inc.
    Via Business Wire
    Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Alto Neuroscience, Inc.
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Maker Of Wilson Tennis Rackets Raises $1.37 Billion In Discounted IPO
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.